Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Haston, Julia C. ; Hwang, Jimee ; Tan, Kathrine R.
• Corporate Authors:
  Emory University School of Medicine. Department of Pediatrics. ; Center for Global Health (U.S.)Division of Parasitic Diseases and Malaria. ; President's Malaria Initiative (U.S.)
• Description:
  An estimated 219 million cases of malaria occurred Worldwide in 2017, causing approximately 435,000 deaths (1). Malaria is caused by intraerythrocytic protozoa of the genus Plasmodium transmitted to humans through the bite of an infective Anopheles mosquito. Five Plasmodium species that regularly cause illness in humans are P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi (2). The parasite first develops in the liver before infecting red blood cells. Travelers to areas with endemic malaria can prevent malaria by taking chemoprophylaxis. However, most antimalarials do not kill the liver stages of the parasite, including hypnozoites that cause relapses of disease caused by P. vivax or P. ovale. Therefore, patients with these relapsing species must be treated with two medications: one for the acute infection, and another to treat the hypnozoites (antirelapse therapy). Until recently, primaquine was the only drug available Worldwide to kill hypnozoites. Tafenoquine, a long-acting 8-aminoquinoline drug related to primaquine, was approved by the Food and Drug Administration (FDA) on July 20, 2018, for antirelapse therapy (Krintafel) and August 8, 2018, for chemoprophylaxis (Arakoda) (3,4). This report reviews evidence for the efficacy and safety of tafenoquine and provides CDC guidance for clinicians who prescribe chemoprophylaxis for travelers to areas with endemic malaria and treat malaria.
• Subjects:
  Aminoquinolines Antimalarials. Full Report Humans Malaria Practice Guidelines As Topic Randomized Controlled Trials As Topic Secondary Prevention Travel Medicine
• Source:
  MMWR Morbidity Mortal Weekly Rep. 68(46):1062-1068
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  31751320
• Pubmed Central ID:
  PMC6871897
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  68
• Issue:
  46
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:7bac9649c38ed67b198bec31cc105a52f325b1d5a2350f0520c833efa36dbbc0c378d464a11aebc3b239ae1e3ff304c32ec92bebff208834fd5cfdfd93a526c8
• Download URL:
  https://stacks.cdc.gov/view/cdc/83968/cdc_83968_DS1.pdf
• File Type:
  [PDF - 464.45 KB ]